TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05001763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prucalopride
Description: Prucalopride, 2mg, tablet. First given 2 days before surgery beginning on POD 1, until defecation or for a maximum of 7 days of postoperative treatment
Study: NCT05185024

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blank Liquid
Description: Once daily dose of 5 ml of Blank Liquid (excipients only) for 12 weeks in total.
Study: NCT05001763

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Glucose, 2mg, tablet.
Study: NCT05128331

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: spermidineLife
Description: dietary supplement that is made of natural wheat germ extract with high spermidine content

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: dietary supplement that is made of cellulose.
Study: NCT05832268

Intervention type: OTHER
Intervention: Obstetric Anal Sphincter Injury
Description: We will investigate if a new vaginal delivery in those with a previous obstetric anal sphincter injury affects the function of anal musculature negatively
Study: NCT05274568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]UCB-2897
Description: Investigational Agent:~\[18F\]UCB2897 is a clear solution formulated for intravenous (IV) injection. The product \[18F\]UCB2897is delivered in normal saline (0.9 % sodium chloride \[NaCl\]) formulated with the intent to contain approximately 3.3 % (v/v) ethanol (EtOH), polysorbate-80 (PS-80, 3.73 μL/mL) and sodium ascorbate (4.67 mg/mL). The final product bears a label with the following items: total activity (mCi), volume (mL), strength (mCi/mL), calibration date and time, batch number, and shelf life. \[18F\]UCB2897 will be stored at ambient temperature in its original container.
Study: NCT05381883

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Participants will answer socio-demographic questions, questions about the lifetime experience of potentially traumatic events, the presence of a known psychological or medical disorder and the taking of medication, and a series of psychological assessment questionnaires.~The questionnaires, performed outside routine care, are as follows :~Posttraumatic stress disorder Checklist for Diagnostic and Statistical Manual of Mental Disorders-5 Beck Depression Inventory-Fast Screen General Anxiety Disorder-7 Coping Inventory for Stressful Situations Maslach Burnout Inventory Medical Outcomes Study Short-Form~The total time for completing the questionnaires is estimated at 20 minutes
Study: NCT05826236

Intervention type: DEVICE
Intervention: Periarticular compression
Description: Periarticular knee compression using a sphygmomanometer.

Intervention type: DEVICE
Intervention: Periarticular compression
Description: Periarticular knee compression using a sphygmomanometer.
Study: NCT05569395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuro mobilization
Description: For median nerve stretching, the participants' dominant forearms will be in the supination position while the shoulder will be depressed and abducted 90 degrees.~In this position, while the participant's head is lateral flexed to the opposite side, the wrist and finger will be extended and median nerve stretching will be performed. After staying in this position for 30 seconds, the participants will relax by placing the wrist and head in the neutral position. Thus, a set for median nerve stretching will be completed. For median nerve gliding, the dominant side of the individuals' forearms will be in supination, while the shoulder will be placed in a depression and 90 degree abduction position. In this position, the participant will flex the wrist and fingers while lateral flexing the head to the opposite side, and extend the wrist and fingers while the head is lateral flexed to the same side.
Study: NCT05603169

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High intensity resistance Exercise Training
Description: The resistance training will consist of five resistance exercises (thrice a week on non-consecutive days): squat, leg press, knee extension, lunges, and abdominal crunches. Every participant will be assessed pre and post intervention for hormonal change, BMI/anthropometric measures, fasting glucose and quality of life.The plan will be followed for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High intensity aerobic Exercise Training
Description: The training protocol will begin with a 5-minute warm-up and will end with a 5-minute cool down, during which the HR will be 60-75% of the HRmax. At least 90 min of exercise per week for obese PCOS patients, with treadmill walking that may include whole-body movement involving more than 2/3 of the muscles, the exercise intensity will be high intensity
Study: NCT05569395

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham neuro mobilization
Description: Sham neuromobilization will be applied to the nondominant side upper extremities of the participants.
Study: NCT05734313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified protocol for cognitive behavioral therapy (UP-CBT)
Description: UP-CBT consists of approximately 16 individual sessions of CBT, conducted over the course of approximately 20 weeks. The UP-CBT consists of 5 core modules targeting negative emotionality and aversive reactions to emotional experiences. These modules are preceded by an introductory session that reviews the patient's presenting symptoms and provides a therapeutic rationale, as well as a module on motivational enhancement. The final module consists of relapse prevention. UP-CBT sessions will integrate a review of Continuous Glucose Monitoring (CGM) data and feedback will be provided by the therapist.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Glucose Monitoring (CGM)
Description: Use of commercially available, FDA-approved continuous glucose monitoring (CGM) for 6 months post-randomization. Usual diabetes care will continue and participants can initiate a CGM review from their healthcare providers, as desired. In addition, a nurse practitioner with expertise in CGM will train each participant via video recordings in the proper placement of the device, and technical issues, and provide basic teaching at the beginning of the trial on interpretation of CGM data and self-titration of insulin/self-management. Written materials and online resources for recognizing and managing anxiety and depressive disorders, along with self-management information and treatment options to discuss with providers will also be provided.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Description: Use of commercially available, FDA-approved continuous glucose monitoring (CGM) for 6 months post-randomization. Usual diabetes care will continue and participants can initiate a CGM review from their healthcare providers, as desired. In addition, a nurse practitioner with expertise in CGM will train each participant via video recordings in the proper placement of the device, and technical issues, and provide basic teaching at the beginning of the trial on interpretation of CGM data and self-titration of insulin/self-management. Written materials and online resources for recognizing and managing anxiety and depressive disorders, along with self-management information and treatment options to discuss with providers will also be provided.
Study: NCT06532006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX22
Description: HLX22 15mg/kg Q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab 8 mg/kg loading dose and then 6 mg/kg maintenance thereafter ,Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab 8 mg/kg loading dose and then 6 mg/kg maintenance thereafter ,Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m2 ,Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m2 ,Q3W

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2 bid on Days 1-14 ,Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m2 bid on Days 1-14 ,Q3W
Study: NCT06141954

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound waves therapy
Description: Therapeutic ultrasound is proposed to deliver energy to deep tissue sites through ultrasonic waves, to produce increases in tissue temperature or non- thermal physiologic changes. Low level laser therapy penetrates particularly light waves that increase cellular metabolism.
Study: NCT04616651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Survey
Description: Participants respond to online survey questions either before or after using the Chatbot O2O intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Survey
Description: Participants respond to online survey questions either before or after using the Chatbot O2O intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chatbot prototype
Description: An online, automated, menu-based agent in which all responses are pre-programmed to be consistent with the existing O2O program. The chat-like responses help guide the participant through a process with the goal of developing a list of questions for their upcoming appointment with a cancer clinician. The session is meant to be completed in one sitting and estimated to take about 45 minutes to complete (including the pre- or post-intervention survey); however, if a participant stops in the middle, they may go back and complete the Chatbot session (or survey).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chatbot prototype
Description: An online, automated, menu-based agent in which all responses are pre-programmed to be consistent with the existing O2O program. The chat-like responses help guide the participant through a process with the goal of developing a list of questions for their upcoming appointment with a cancer clinician. The session is meant to be completed in one sitting and estimated to take about 45 minutes to complete (including the pre- or post-intervention survey); however, if a participant stops in the middle, they may go back and complete the Chatbot session (or survey).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Open to Options (O2O) Program
Description: Evidence-based program developed by Cancer Support Community that helps patients actively engage in their treatment decision process by preparing them for their upcoming appointments.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Open to Options (O2O) Program
Description: Evidence-based program developed by Cancer Support Community that helps patients actively engage in their treatment decision process by preparing them for their upcoming appointments.
Study: NCT03604250

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lifestyle plus prebiotic supplement
Description: Research participants will be asked to wear health monitoring devices, including a continuous glucose and heart-rate monitors. They may be prompted to perform lifestyle modifications aimed at better understanding their health parameters, based on the results obtained from the wearable devices and other tests. During the last 3 weeks of the study, research participants may be asked to take a personalized prebiotic supplement, up to once/day.
Study: NCT05694624

Intervention type: DRUG
Intervention: Para Aminohippurate
Description: Measurements of renal plasma flow and glomerular filtration rate

Intervention type: DRUG
Intervention: Para Aminohippurate
Description: Measurements of renal plasma flow and glomerular filtration rate
Study: NCT05409417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental drug
Description: Tilelizumab combined with XELOX and bevacizumab or tislelizumab combined with FOLFOX and cetuximab
Study: NCT06141954

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low level laser therapy
Description: Low-level laser (light) therapy (LLLT) is a fast-growing technology used to treat a multitude of conditions that require stimulation of healing, relief of pain and inflammation, and restoration of function.
Study: NCT05927129

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antidepressant
Description: Patients will receive standardized treatment with antidepressant, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy IPT
Description: The participants will receive standardized IPT treatment for 12 weeks. Patients will receive standardized treatment, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The combination of antidepressant and IPT
Description: The participants will receive standardized IPT treatment for 12 weeks. Also，long-term antidepressant will be administered in accordance with clinical guidelines. Patients will receive standardized treatment, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.
Study: NCT05201157

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: acupressure group
Description: A suitable environment will be prepared for mothers in terms of warmth and light, where privacy can be protected. The application points will be determined with the acu-point device by choosing the most comfortable position of the mother, leaving the application points exposed. The most preferred points ST36, LI4 and SP6 were selected from the points reported to affect lactation by reviewing the literature on the points to be compressed. Acupressure will be applied to points (bidirectional, right and left) for 2 minutes for a total of 6 minutes. Light pressure will be applied with the thumb of the practitioner's hand. Immediately after applying pressure for 2 minutes for each point, it will be moved to the other point in the symmetrical region and the application will be made without interruption. While practicing, the researcher will control the time using a digital wrist watch with a stopwatch

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: No application will be made. The mothers in this group will fill in the Visual Similarity Scale for Fatigue twice, once between 8-12 hours post-op and once on the post-op 2nd day.
Study: NCT04487613

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moringa oleifera leaf
Description: 450 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule
Study: NCT06390904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Description: Gonadotropin-releasing hormone analogue, intramuscular injection of 3.75mg will be given every 4 weeks, and the maximum treatment courses will be 6. If the patient get CR within 6 courses, another 2 courses will be used as consolidation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: 2.5mg po qd.
Study: NCT05026957

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SharedHeart
Description: A smartphone application

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SharedHeart
Description: A smartphone application
Study: NCT05593783

Intervention type: PROCEDURE
Intervention: lithotripsy
Description: lithotripsy

Intervention type: PROCEDURE
Intervention: lithotripsy
Description: lithotripsy
Study: NCT06532578

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPX101 or placebo 120mg Q2W
Description: Subcutaneous injection of CPX101 or placebo
Study: NCT04934670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-Guard
Description: T-Guard will be administered intravenously inpatient over 4 hours every 2 calendar days on Days 0, 2, 4, and 6, at a dose of 4mg/m2 Body Surface Area (BSA).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib
Description: Ruxolitinib will be administered orally twice a day starting on Day 0 through Day 56, at a dose of 10mg. Ruxolitinib taper can be initiated starting on Day 56 for participants responding to treatment, tapering will be done according to institutional practices.
Study: NCT04338815

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exoskeleton optimization
Description: Participants will walk 10 times of 1 minute duration while an optimization algorithm changes the assistance profile of an exoskeleton.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance evaluation
Description: Participants will walk 2 times at a speed of 1 meter per second until the participant indicates claudication or a maximum duration of 6 minutes.
Study: NCT05593783

Intervention type: PROCEDURE
Intervention: lithotripsy
Description: lithotripsy
Study: NCT06135519

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Mesenchymal stem cells injection
Description: Autologous Mesenchymal stem cells will be seperated from harvested fat and injected in acne scars

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Homogenized fat injection
Description: Autologous fat will be harvested, homogenized and injected.
Study: NCT06532578

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPX101 or placebo 160mg Q4W
Description: Subcutaneous injection of CPX101 or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPX101 or placebo 160mg Q2W
Description: Subcutaneous injection of CPX101 or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPX101 or placebo 240mg Q4W
Description: Subcutaneous injection of CPX101 or placebo

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CPX101 or placebo 240mg Q2W
Description: Subcutaneous injection of CPX101 or placebo
Study: NCT06066112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Test (T) Amisulpride orally disintegrating tablets (200mg). Produced and supplied by Zezheng (Shanghai) Biotechnology Co., Ltd.
Description: Randomly assign to TR or RT sequence groups based on a predetermined random table and receive the corresponding study drug according to the corresponding administration sequence.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Test (T) Amisulpride orally disintegrating tablets (200mg). Produced and supplied by Zezheng (Shanghai) Biotechnology Co., Ltd.
Description: Randomly assign to TR or RT sequence groups based on a predetermined random table and receive the corresponding study drug according to the corresponding administration sequence.
Study: NCT06529497

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racecadotril
Description: The intervention group will receive racecadotril+ORS+Zinc

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Racecadotril
Description: The intervention group will receive racecadotril+ORS+Zinc
Study: NCT06336070

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT program (8 weeks)
Description: Metabolic Power Training: A High Intensity Interval Training (HIIT) intervention, 3 times per week (30 min session) during 8 weeks with professional supervision and intensities adapted and modified during the intervention period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MPI program (8 weeks)
Description: Muscle Power Intervention (MPI), 2 times per week (45 min session) during 8 weeks with professional supervision and intensities adapted and modified during the intervention period.
Study: NCT06389812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-task exercise traning
Description: To assess the dynamic effects of each intervention, only one session (30 mins) will be provided. The chair-based exercise session consists of three parts 5 min of active stretching exercises to warm-up, 20 mins of resistance band exercises in a sitting position (Elliott-King et al., 2019) (please see the link for detailed descriptions for seated resistance band workout) and 5 min of passive stretching exercises to cold down. The motor-cognitive dual-task group will be additionally asked to do horizontal eye movements by watching a TV screen and following a duck moving from side to side (bilateral condition) while performing strengthening exercises. The duck moves successively between left and right banks of a river at a rate of 500 ms (Brunyé et al., 2009) which was previously found to improve cognitive function

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dual-task exercise traning
Description: To assess the dynamic effects of each intervention, only one session (30 mins) will be provided. The chair-based exercise session consists of three parts 5 min of active stretching exercises to warm-up, 20 mins of resistance band exercises in a sitting position (Elliott-King et al., 2019) (please see the link for detailed descriptions for seated resistance band workout) and 5 min of passive stretching exercises to cold down. The motor-cognitive dual-task group will be additionally asked to do horizontal eye movements by watching a TV screen and following a duck moving from side to side (bilateral condition) while performing strengthening exercises. The duck moves successively between left and right banks of a river at a rate of 500 ms (Brunyé et al., 2009) which was previously found to improve cognitive function
Study: NCT06370637

Intervention type: OTHER
Group type: OTHER
Intervention: MASD Control Arm
Description: Tthe research coordinator HANS team will provide participants with a daily survey, a weekly survey, a Bristol stool scale and a 200 ml container with the specific cream for the arm assigned. Participants will be directed to apply the cream liberally after each bowel movement after cleaning the area in their usual manner. The research coordinator HANS team will review the instructions of application with the patient.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MASD Control Arm
Description: Tthe research coordinator HANS team will provide participants with a daily survey, a weekly survey, a Bristol stool scale and a 200 ml container with the specific cream for the arm assigned. Participants will be directed to apply the cream liberally after each bowel movement after cleaning the area in their usual manner. The research coordinator HANS team will review the instructions of application with the patient.